Chronic Kidney Disease (CKD) is characterized by iron deficiency (ID), inflammation, and increased skeletal and extra-skeletal production of fibroblast growth factor (FGF)-23 that is associated with cardiovascular mortality. Secretion of NGAL from the injured kidney and reduced expression of miR122-5p directly stimulate FGF23 production. This project proposes to test the contribution of extra-skeletal sources of FGF23 to FGF23 excess in response to NGAL, ID, inflammation and CKD, and to test the role of miR122-5p on the post-translational modifications of FGF23, thus providing potential therapeutic target for individuals with CKD.
|Effective start/end date||9/17/20 → 6/30/25|
- National Institute of Diabetes and Digestive and Kidney Diseases (2R01DK102815-06)